A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade

Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Mar 18, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how certain immune cells in the lungs and blood of cancer patients can help us understand and identify the effects of immunotherapy treatments, particularly when these treatments lead to lung problems known as pneumonitis. The researchers are collecting samples from patients who are undergoing a procedure called bronchoscopy, which allows them to gather fluid from the lungs. By examining this fluid at a very detailed level, they hope to find markers that can indicate if a patient is experiencing lung toxicity from their cancer treatment. Additionally, they aim to discover if blood tests can provide similar information without needing invasive procedures.

To participate in this study, you need to be an adult aged 18 or older who is currently receiving or has previously received cancer treatment and is undergoing bronchoscopy due to potential lung issues related to that treatment. You should not be involved in any other clinical trials and must provide consent to take part. If you join, you can expect to provide samples that will help researchers learn more about how immunotherapy might affect the lungs, which could lead to better ways to diagnose and treat these side effects in the future.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Adult M/F/X (\>= 18 years)
• • Patients receiving or having received treatment per guidelines
• • Patients undergoing bronchoscopy with BAL, for possible cancer treatment-induced pneumonitis
• • Not included in other clinical trials
• • Signed informed consent form
• Exclusion criteria:
• • • Collected material not suitable for further processing in this study (e.g. bad quality). This decision will be made in consultation with a lab technician and/or bio-informatician, specialized in single-cell analysis.